ANE URANGA ECHEVERRIA-rekin lankidetzan egindako argitalpenak (29)

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2023

  1. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Science of the Total Environment, Vol. 894

  2. Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents

    Aging Clinical and Experimental Research, Vol. 35, Núm. 8, pp. 1771-1778

  3. Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia

    Infection, Vol. 51, Núm. 5, pp. 1319-1327

  4. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

    Frontiers in Medicine, Vol. 10

  5. Leukocyte differential and cell population data in the evaluation of SARS-CoV-2 and other infections

    Journal of Laboratory and Precision Medicine, Vol. 8

  6. Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing

    International Journal of Infectious Diseases, Vol. 134, pp. 106-113

2022

  1. Author Correction: Machine learning-based model for prediction of clinical deterioration in hospitalized patients by COVID 19 (Scientific Reports, (2022), 12, 1, (7097), 10.1038/s41598-022-09771-z)

    Scientific Reports

  2. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences

    Infection, Vol. 50, Núm. 1, pp. 179-189

  3. Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia Collaboration Cohort

    Respiratory Medicine, Vol. 200

  4. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781

  5. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia

    Journal of Infection, Vol. 85, Núm. 6, pp. 644-651

  6. Utility of Differential White Cell Count and Cell Population Data for Ruling Out COVID-19 Infection in Patients With Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 58, Núm. 12, pp. 802-808

2021

  1. Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia (BMC Pulmonary Medicine, (2020), 20, 1, (261), 10.1186/s12890-020-01293-6)

    BMC Pulmonary Medicine

  2. Predictors of mortality of COVID-19 in the general population and nursing homes

    Internal and Emergency Medicine, Vol. 16, Núm. 6, pp. 1487-1496

2020

  1. Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Guidelines. 2020 Update

    Archivos de Bronconeumologia

  2. Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 56, Núm. 9, pp. 551-558

  3. Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome

    Infectious Diseases, Vol. 52, Núm. 9, pp. 603-611

  4. Q Fever (Coxiella Burnetii)

    Seminars in Respiratory and Critical Care Medicine, Vol. 41, Núm. 4, pp. 509-521

2019

  1. Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001–2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain)

    Vaccine, Vol. 37, Núm. 29, pp. 3840-3848